论文部分内容阅读
目的:探讨髓样分化因子88(MyD88)在喉癌组织中的表达及临床意义。方法:收集喉癌患者51例,所有患者术后均经病理诊断结果证实,通过免疫组织化学方法检测MyD88蛋白在喉癌及其癌旁组织中的表达,并探讨MyD88表达量与临床病理特征和患者预后的相关性。结果:MyD88在喉癌组织中阳性表达率为68.6%,明显高于癌旁正常组织中的阳性表达率11.8%(P<0.01);MyD88的阳性表达率与喉癌患者的年龄、性别、分化程度和肿瘤部位无关(P>0.05),与临床分期(P<0.01)和淋巴结转移(P<0.05)呈正相关。MyD88的表达量与患者的5年生存率呈反比,高表达MyD88的患者5年生存率显著低于低表达者(P<0.05)。结论:MyD88可能是喉癌发病机制中的重要参与者,靶向MyD88的治疗有可能改善喉癌患者的预后。
Objective: To investigate the expression of myeloid differentiation factor 88 (MyD88) in laryngeal carcinoma and its clinical significance. Methods: Fifty-one patients with laryngeal cancer were collected. All patients were confirmed by pathological diagnosis after operation. The expression of MyD88 protein in laryngeal carcinoma and its adjacent tissues was detected by immunohistochemistry. The expression of MyD88 and clinicopathological features were analyzed. Correlation of patient prognosis. Results: The positive expression rate of MyD88 in laryngeal carcinoma was 68.6%, which was significantly higher than that in adjacent normal tissues (11.8%, P <0.01). The positive expression rate of MyD88 was significantly correlated with the age, sex, (P <0.05), but not with tumor stage (P> 0.05), but positively correlated with clinical stage (P <0.01) and lymph node metastasis (P <0.05). The expression of MyD88 was inversely correlated with the 5-year survival rate of patients, and the 5-year survival rate of patients with high MyD88 expression was significantly lower than that of low expression (P <0.05). Conclusion: MyD88 may be an important participant in the pathogenesis of laryngeal cancer. The treatment of MyD88 may improve the prognosis of laryngeal cancer patients.